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In a case-control study of occupational and environmental causes of cryptogenic fibrosing alveolitis we 
recently observed a higher prevalence of self-reported symptoms of wheeze, rhinitis or conjunctivitis in 
cases than in controls. To determine objectively whether this was due to a higher prevalence of atopy 
amongst cases of CFA, we have measured skin sensitivity to common allergens (D. Pteronyssinus, grass 
pollen, and cat fur), eosinophil counts and total Immunoglobulin E (IgE) in venous blood in the 22 
surviving CFA cases from that study who were willing to provide a blood sample, and in one matched 
control per case. At least one positive skin test was recorded in 13 cases and six controls, the matched odds 
of one or more positive test being significantly increased in cases by a ratio of 8.0 (95% confidence interval 
1.0164, P=O.O5). Geometric mean eosinophil counts and IgE levels were also increased amongst cases by 
factors of 1.6 (95% CI 0.96-2.6) and 1.9 (0.9-3.8) respectively, although these differences were not 
significant. Differences in skin sensitivity, eosinophil counts, and IgE levels all tended to be more obvious 
in the 13 case control pairs in which the case was not taking steroids or other immunosuppressive 
treatment. We conclude that cases of CFA showed increased skin sensitivity to common allergens, and had 
evidence of increased IgE and eosinophilia in peripheral blood. These findings suggest that atopy may be 
an important determinant of susceptibility to CFA. 
Introduction 
The aetiology of cryptogenic fibrosing alveolitis 
(CFA) is unknown. In a recent case-control study 
of potential environmental causes of CFA, we 
observed incidentally that cases of CFA were more 
than twice as likely than individually matched com- 
munity controls to report symptoms consistent with 
asthma, rhinitis or conjunctivitis after exposure to 
pollen or household dust (1). This suggested that 
atopy may be a risk factor for CFA, but because we 
did not obtain objective measurements of atopic 
status in that study, we were unable to exclude the 
alternative explanation that the association was due 
to biased reporting of symptoms by our cases. We 
have now measured allergen skin sensitivity, serum 
IgE and blood eosinophil counts in surviving cases 
from that study, and present these results in com- 
parison with data from individually matched 
controls. 
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Subjects and Methods 
Of 43 patients with CFA studied in 1989 (1) and 
who represented all cases of CFA known to 
Nottingham City and University Hospitals willing to 
take part in the study at the time, 23 were still alive in 
autumn 1991, and 22 agreed to take part in the 
present study. All cases had documented inspiratory 
basal crackles, bilateral interstitial shadowing on the 
chest X-ray film, restrictive pulmonary function, and 
a noted absence of exposure to known fibrogenic 
agents. Individually matched controls were obtained 
by contacting sequentially the individuals of the same 
sex and closest in age to the index case on the same 
general practitioner age-sex register, and asking for 
their cooperation with the study; this process contin- 
ued until one control per case had agreed to take 
part. For 19 of the cases, the control subject was one 
of those who had acted as a control in our previous 
study (I), for the other three cases none of the 
previous controls was either available or willing to 
take part so a new control subject was recruited. 
Skin sensitivity to D. Pteronyssinus, grass pollen 
and cat fur allergen extracts (Bencard U.K.) were 
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Table I Age, sex, skin test, IgE and eosinophil data, and matched differences and 95% confidence intervals, for all 
case-control matched pairs, and for pairs broken down according to whether the case was taking steroids with or without 
other immunosuppressive therapy at the time of the study 
All 
cases Controls 
Cases on 
steroids Controls 
Cases not on 
steroids Controls 
Number 22 22 9 9 13 13 
Males 14 
Mean (SD) age 65 (7.5) Ii: (7.5) B (6.0) ti (6.0) :: (9.2) :: (9.2) 
2 1 positive skin test 
Positive skin tests in 
discordant matched pairs 
Mean (SD) log,, 
IgE (kU 1-l) 
Mean (SE) log,, 
difference 
(95% CI) 
Mean (SD)log,, 
eosinophils ( x lo6 1-l) 
Mean (SE) log,, 
difference 
(95% CI) 
13 
8 
1.65 (0.8) 
0.27 
(-0.04, 
2.22 (0.6) 
0.20 
(-0.02, 
6 
1 
1.36 
(0.15) 
0.58) 
2.01 
(0.10) 
0.42) 
W9 
(0.5) 
3 2 10 
2 1 6 
.15 (0.7) 1.14 (0.5) 2.0 (0.7) 1.51 (0.5) 
-0.08 (0.11) 0.45 (0.23) 
(-0.33, 0.18) (-0.04, 0.94) 
.90 (0.8) 2.02 (0.8) 2.44 (0.3) 2.02 (0.3) 
-0.14 (0.18) 0.39 (0.08) 
(-0.56) 0.28) (0.23, 0.56) 
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measured in all cases and controls by skin prick 
testing, and venous blood taken for total IgE estima- 
tion and eosinophil counts. Skin tests were consid- 
ered positive if any allergen wheal diameter exceeded 
the saline response by 1 mm or more. The odds ratio 
for disease given positive skin tests was calculated 
and tested for significance using McNemar’s test for 
matched designs (2), and approximate 95% confi- 
dence intervals estimated by conditional logistic 
regression. IgE levels and eosinophil counts were 
log-transformed and compared between cases and 
matched controls by paired t-tests. To explore the 
possibility that current steroid or other immunosup- 
pressive therapy may inhibit skin test responses or 
suppress IgE or eosinophil levels, we repeated these 
comparisons within case-control pairs subgrouped 
according to whether the case was using steroid or 
other immunosuppressive therapy at the time of the 
study. The study was approved by the City Hospital 
Ethics Committee. 
Results 
The matched odds of having any positive skin test 
were increased in cases by a ratio of 8.0 (PcO.05, 
approximate 95% confidence interval 1.01-64). Geo- 
metric mean IgE levels and eosinophil counts were 
also increased in cases, though not to the point of 
statistical significance, by factors of 1.9 (0.95-4.0, 
P=O.O7) and 1.6 (0.962.6, P=O.O7) respectively. Dif- 
ferences in the prevalence of positive skin tests, and 
in IgE levels and eosinophil counts all tended to be 
more marked in the subgroup of 13 case-control pairs 
in which the case was not receiving steroid or other 
immunosuppressive therapy (Table l), though the 
numbers involved in these subgroups were small and 
formal statistical comparison is probably inappropri- 
ate. There was no difference between cases and 
controls in the prevalence of smoking, and none was 
using antihistamine medications. 
Discussion 
Having previously found that cases of CFA 
reported a higher prevalence of symptoms consistent 
with allergic disease than a population of individually 
matched controls, we have now demonstrated signifi- 
cantly increased odds of allergen skin sensitivity 
amongst survivors from that group of CFA cases. 
Although based on small numbers, this study there- 
fore confirms that the increased reporting of allergic 
symptoms by CFA cases in our previous investiga- 
tion was more likely to have been due to a higher 
prevalence of atopy amongst cases than an artefact of 
reporting bias. The prevalence of atopy in our con- 
trol population was approximately 25%, which is as 
expected for a population of this age (3). Our finding 
that serum IgE levels and eosinophil counts were also 
higher amongst cases, although not statistically sig- 
nificant, supports this conclusion. Atopy appeared to 
be more frequent amongst cases who did not require 
regular steroid or immunosuppressive therapy, which 
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although based on small subgroups suggests either References 
that steroids suppress the expression of atopy in 
CFA, or that atopy, by virtue of being associated 
1, 
with relatively long survival without regular therapy, 
is a favourable prognostic factor in CFA. 2. 
So far as we are aware, apart from evidence 
documenting the presence of eosinophils in broncho- 3. 
alveolar lavage samples from cases of CFA (4), this is 
the first reported evidence that CFA may be linked 
with systemic markers of atopy. The suggestion that 4. 
atopy may be involved in the pathogenesis of CFA is 
supported however by evidence that mast cells, which 
have an established pathogenetic role in other atopic 
diseases, are found in increased numbers and in 
5. 
relation to the severity of fibrosis in the lungs of 
patients with CFA (5). Close physical apposition of 6. 
mast cells to fibroblasts in the alveolar walls is also 
documented in patients with CFA (6), as is the 
stimulation of fibroblast proliferation by mast cell 
products in vitro (7,8). Mast cells may therefore act as 
7, 
effector cells for allergic stimuli initiating the patho- 
genesis of lung fibrosis. We conclude that the role of 8. 
atopy in the aetiology, pathogenesis and prognosis of 
CFA justifies further investigation. 
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